Assembly Biosciences (ASMB) announced Phase 1b clinical data for its next-generation investigational capsid assembly modulator, CAM, ABI-4334 featured in a late-breaking poster presentation at the American Association for the Study of Liver Diseases, AASLD, The Liver Meeting. The conference is taking place November 7-11, 2025, in Washington, D.C. The late-breaking poster presentation titled “Safety, pharmacokinetics and antiviral activity of the next-generation hepatitis B capsid assembly modulator ABI-4334 in patients with HBeAg-negative chronic hepatitis B infection not suppressed on nucleoside analogues: results from a randomized, blinded, Phase 1b study” highlights data in individuals with chronic hepatitis B infection treated with ABI-4334. This poster is the first scientific presentation of the complete Phase 1b data announced earlier this year by Assembly Bio.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASMB:
- ASMB Earnings this Week: How Will it Perform?
- Assembly Biosciences Advances HSV-2 Treatment Study with ABI-1179
- Assembly Biosciences’ Promising HSV-2 Treatment Study: Key Insights for Investors
- Assembly Biosciences’ ABI-6250 Study: A Potential Game-Changer in Hepatitis Treatment
- Assembly Biosciences files to sell 6.98M shares of commons stock for holders